Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to -$1.8 million.

  • Lineage Cell Therapeutics' Other Working Capital Changes rose 4741.51% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.1 million, marking a year-over-year decrease of 1853.16%. This contributed to the annual value of -$7.7 million for FY2024, which is 45.78% down from last year.
  • According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Other Working Capital Changes is -$1.8 million, which was up 4741.51% from -$2.5 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' Other Working Capital Changes' 5-year high stood at $807000.0 during Q3 2021, with a 5-year trough of -$4.9 million in Q1 2022.
  • Its 5-year average for Other Working Capital Changes is -$1.8 million, with a median of -$1.8 million in 2022.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Other Working Capital Changes soared by 52031.25% in 2021 and then crashed by 538804.35% in 2022.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Other Working Capital Changes stood at -$849000.0 in 2021, then tumbled by 107.66% to -$1.8 million in 2022, then grew by 8.74% to -$1.6 million in 2023, then tumbled by 54.07% to -$2.5 million in 2024, then increased by 28.2% to -$1.8 million in 2025.
  • Its last three reported values are -$1.8 million in Q3 2025, -$2.5 million for Q2 2025, and -$1.3 million during Q1 2025.